# Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers

> **NCT02723630** · PHASE1 · COMPLETED · sponsor: **Eisai Inc.** · enrollment: 60 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Lenvatinib 10 mg

## Key facts

- **NCT ID:** NCT02723630
- **Lead sponsor:** Eisai Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07
- **Primary completion:** 2013-08
- **Final completion:** 2013-08
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2019-03-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02723630

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02723630, "Bioequivalence Study to Evaluate the Impact of Varying Crystalline Polymorph Forms for the Commercial Oral Capsule Formulation of 10-mg Lenvatinib in Healthy Volunteers". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02723630. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*